Instituto de Medicina Molecular, Cenix BioScience, and Alnylam Pharmaceuticals Discover New Pathway for Malaria Infection.
Business Wire (September 11, 2008)
Permanent Link:
http://vlex.com/vid/instituto-medicina-cenix-pathway-malaria-56070446
Id. vLex: VLEX-56070446
Acceda a este documento
y pruebe vLex GRATIS durante 3 días
Business
Business, general
Biotechnology industries
Research
Medical research
Pharmaceutical industry
Cholesterol
Malaria
Drug therapy
Health aspects
Instituto de Medicina Molecular, Cenix BioScience, and Alnylam Pharmaceuticals Discover New Pathway for Malaria Infection.
- New Research using RNAi Technologies Published on the First Molecular Link between Malaria and the Host Cholesterol Uptake Pathway -
LISBON, Portugal & DRESDEN, Germany & CAMBRIDGE, Mass. -- Cenix BioScience GmbH, a leading specialist in advanced RNA interference (RNAi)-based research services, Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and the Lisbon-based biomedical research centre Instituto de Medicina Molecular (IMM), today announced the publication of their collaborative study in Cell Host & Microbe, describing the discovery and in vivo validation of scavenger receptor BI (SR-BI), a major regulator ...Try vLex for FREE for 3 days
Access legal information from United States including:
- Constitutions
- Forms and Contracts
- Legal Books and Journals
- Case Law
- News and Business
- Regulations
- U.S. Code
Try vLex without any commitment for 3 days and see why you need it.
3
days of Free Access
If you are already a vLex customer, Access Here
